PA
Pacific Biosciences of California, Inc.
PACB · NASDAQ
$2.30 -15.44% (-$0.42)
1M +110.85%
Market Cap $714.4M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$3.12
35.7% upside
Current Price
$2.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PACB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
40 /100
Fair P/S 4.49x
P/E N/A
EV/EBITDA N/A
Growth
44 /100
Stable Rev. growth 7.64%
Book val. growth 78.82%
EPS growth N/A
Profitability
14 /100
Weak Gross margin 35.97%
Net margin 82.49%
Op. margin 102.05%
Quality
4 /100
Poor ROIC 23.90%
ROA 17.48%
Asset turnover 0.21x
Debt
43 /100
Moderate Current ratio 4.92x
Int. coverage -32.92x
Debt/Equity N/A
Stability
14 /100
Unstable Beta 2.31x
Rev. volatility 40.41%
EPS volatility 47.74%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PACB
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Mark Van Oene
Employees
485
Headquarters
Menlo Park
Upcoming events
03 NOV
Earnings
Upcoming earnings report
09 FEB
Earnings
Upcoming earnings report